Department of Neuroradiology, University Medical Center Mannheim, Medical Faculty Mannheim, University of Heidelberg, Germany.
Department of Neuroradiology, University Medical Center Mannheim, Medical Faculty Mannheim, University of Heidelberg, Germany.
J Neuroradiol. 2020 Mar;47(2):166-173. doi: 10.1016/j.neurad.2019.01.090. Epub 2019 Jan 16.
Post-radiation treatment effects (pseudoprogression/radionecrosis) may bias MRI-based tumor response evaluation. To understand these changes specifically after high doses of radiotherapy, we analyzed MRIs of patients enrolled in the INTRAGO study (NCT02104882), a phase I/II dose-escalation trial of intraoperative radiotherapy (20-40 Gy) in glioblastoma.
INTRAGO patients were evaluated and compared to control patients who received standard therapy with focus on contrast enhancement patterns/volume, T2 lesion volume, and mean rCBV.
Overall, 11/15 (73.3%) INTRAGO patients (median age 60 years) were included. Distant failure was observed in 7/11 (63.6%) patients, local tumor recurrence in one patient (9.1%). On the first follow-up MRI all but one patient demonstrated enhancement of varying patterns around the resection cavity which were: in 2/11 (18.2%) patients thin and linear, in 7/11 (63.6%) combined linear and nodular, and in 1/11 (9.1%) voluminous, indistinct, and mesh-like. In the course of treatment, most patients developed the latter two patterns (8/11 [72.7%]). INTRAGO patients demonstrated more often combined linear and nodular and/or voluminous, indistinct, mesh-like components (8/11 [72.7%]) in comparison to control patients (3/12 [25%], P = 0.02). INTRAGO patients demonstrated significantly increasing enhancing lesion (P = 0.001) and T2 lesion volumes (P < 0.001) in the longitudinal non-parametric analysis in comparison to the control group. rCBV showed no significant differences between both groups.
High doses of radiotherapy to the tumor cavity result in more pronounced enhancement patterns/volumes and T2 lesion volumes. These results will be useful for the response evaluation of patients exposed to high doses of radiotherapy in future studies.
放射后治疗效应(假性进展/放射性坏死)可能会影响基于 MRI 的肿瘤反应评估。为了具体了解高剂量放疗后的这些变化,我们分析了 INTRAGO 研究(NCT02104882)中入组患者的 MRI,该研究为胶质母细胞瘤术中放疗(20-40Gy)的 I/II 期剂量递增试验。
对 INTRAGO 患者进行评估,并与接受标准治疗的对照患者进行比较,重点关注对比增强模式/体积、T2 病变体积和平均 rCBV。
共纳入 15 例 INTRAGO 患者中的 11 例(中位年龄 60 岁)。7/11(63.6%)患者出现远处失败,1 例(9.1%)患者出现局部肿瘤复发。在首次随访 MRI 上,除 1 例患者外,所有患者在切除腔周围均显示出不同模式的增强,包括:2/11(18.2%)患者为线状强化,7/11(63.6%)患者为线样和结节状混合强化,1/11(9.1%)患者为体积大、边界不清、网格状强化。在治疗过程中,大多数患者发展为后两种模式(8/11 [72.7%])。与对照患者(3/12 [25%],P=0.02)相比,INTRAGO 患者表现出更常见的线样和结节状混合强化和/或体积大、边界不清、网格状强化。在纵向非参数分析中,INTRAGO 患者的增强病变(P=0.001)和 T2 病变体积(P<0.001)显著增加,与对照组相比。两组间 rCBV 无显著差异。
肿瘤腔高剂量放疗导致更明显的增强模式/体积和 T2 病变体积。这些结果将对未来研究中接受高剂量放疗的患者的反应评估有用。